Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars

Abstract

Linked Content This article is linked to Goncalves et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14860.

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

“…We thank Peyrin‐Biroulet and colleagues, Mariaangela Alloca and Lieven Pouillan, for their interest in our work . We agree with them that post‐marketing pharmacovigilance, together with prospective and retrospective observational studies, will remain important to detect rare potential immunogenic events.…”

Interchangeability of Biosimilars: Overcoming the Final Hurdles

“…What are the chances of a large divergence in epitopes between biosimilars of the same reference product? A number of researchers, particularly Ben Horin [ 19 ], Ruiz-Argüello [ 20 ], Fiorino [ 21 ], and Goncalves, have worked out a robust methodology to investigate this ex vivo, particularly for infliximab [ 22 , 23 ], and Mysler et al [ 11 ] discuss this work extensively. These results are supported by the emerging real-world clinical data on switching between biosimilars that the authors identify and discuss in detail.…”